Overture Life Earns CE Mark for DaVitri Fertility Automation in Europe
Overture Life Gains CE Mark for Automated IVF Device DaVitri
Overture Life secures CE Mark for DaVitri, becoming the first automated IVF device approved in Europe for egg vitrification and blastocyst-rate claims.
What’s new
Overture Life, an international leader in fertility automation, has received CE Mark approval for its DaVitri platform, enabling the commercialization of their automated in vitro fertilization (IVF) technology across Europe. This certification makes DaVitri the first device in both the European Union and the United States authorized to automate the vitrification—rapid freezing—of unfertilized eggs. Additionally, DaVitri is the first system with regulatory approval to claim lab-validated rates of blastocyst development after thawing, marking a significant advance in fertility technology and clinical reliability.
Why it matters
With declining birth rates worldwide, access to assisted reproduction is a growing concern. Designed as a tabletop device, DaVitri extends egg-freezing capabilities beyond the limitations of traditional fertility centers. By automating the challenging process of vitrifying oocytes, it minimizes user discrepancies, streamlines training, and consistently delivers embryo formation outcomes verified by laboratory testing.
How DaVitri advances IVF
The platform standardizes a delicate procedure that typically depends on expert hands, helping clinics improve reproducibility and throughput. By integrating automation into vitrification, DaVitri supports consistent post-thaw embryo development—now reinforced by regulatory recognition of lab-validated blastocyst outcomes.
“This approval reflects Europe’s recognition of the urgent need for reproductive autonomy.” — Hans Gangeskar, CEO of Overture Life
Gangeskar noted the EU’s commitment to supporting public investment in fertility infrastructure and innovative technologies, expressing hope that other regions will follow suit.
Market context and funding
To date, Overture Life has raised approximately $70 million in funding, mainly from U.S. investors. The high demand in the American market has pushed the cost of one IVF cycle to around $15,000, underscoring the importance of scalable solutions.
Broader portfolio and progress
Overture Life’s portfolio extends beyond vitrification automation, with tools designed to modernize core embryology workflows:
- ICSI.A robot: In 2023, resulted in two live births from fully automated fertilization.
- m|z platform: Powered by AI and metabolomics for non-invasive, healthy embryo selection, now available at a certified laboratory in Texas.
The company integrates engineering and reproductive science to improve efficiency in fertility clinics, aiming to increase success rates and reduce overall costs for patients. Backed by investors such as Overwater Ventures, GV, Khosla Ventures, and Octopus Ventures, Overture Life continues to advance innovations that empower individuals and families to take control of their reproductive futures.
Looking ahead
With CE Mark approval for DaVitri, European clinics can now access a first-of-its-kind automated platform for egg vitrification and lab-validated blastocyst-rate claims. As adoption widens, automation could help standardize outcomes, expand access, and make IVF more attainable for patients worldwide.
